Development of an Aryloxazole Derivative As a Brain-Permeable Anti-Glioblastoma Agent

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Oct 2

PMID 31569420

Authors

Seulgi Shin

Sungsu Lim

Ji Yeon Song

Dohee Kim

Min Jeong Choi

Changdev G Gadhe

A Young Park

Ae Nim Pae

Yun Kyung Kim

Affiliations

Soon will be listed here.

Abstract

Glioblastoma drug development has been difficult due to the extremely low blood brain barrier (BBB) penetration of conventional anti-cancer agents. P-glycoprotein, an efflux membrane transporter, is responsible for the poor brain uptake of small and hydrophobic drug substances. To develop brain-penetrable anti-tumor agents, we designed colchicine derivatives containing an aryloxazole moiety, which is known to inhibit P-glycoprotein. Among those tested, an aryloxazole derivative named KIST-G1 showed the strongest anti-glioblastoma cell proliferation activity (IC = 3.2 ± 0.8 nM). Compared to colchicine, KIST-G1 showed dramatically increased BBB-permeable properties presenting 51.7 ± 0.5 (10 cm/s) parallel artificial membrane permeability assay (PAMPA) permeability and 45.0 ± 6.0% of P-gp inhibition. Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control. In comparison, temozolomide, which is the most widely used drug for glioblastoma, showed only moderate effects. Our results demonstrate the effectiveness of an aryloxazole moiety in targeting brain tumors and suggest KIST-G1 as a potent anti-glioblastoma agent.

References

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

Zhang Y, Zhang G, Sun X, Cao K, Ma C, Nan N . Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett. 2018; 15(5):6233-6240. PMC: 5876452. DOI: 10.3892/ol.2018.8113. View

Clark M, Homer N, OConnor B, Chen Z, Eskin A, Lee H . U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet. 2010; 6(1):e1000832. PMC: 2813426. DOI: 10.1371/journal.pgen.1000832. View

Kluck R, Bossy-Wetzel E, Green D, Newmeyer D . The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997; 275(5303):1132-6. DOI: 10.1126/science.275.5303.1132. View

Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati I, Fogal V . Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med. 2014; 12:13. PMC: 3898565. DOI: 10.1186/1479-5876-12-13. View

Bansal T, Mishra G, Jaggi M, Khar R, Talegaonkar S . Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009; 36(4-5):580-90. DOI: 10.1016/j.ejps.2008.12.005. View

Soldani C, Scovassi A . Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002; 7(4):321-8. DOI: 10.1023/a:1016119328968. View

Koo H, Shin S, Choi J, Lee K, Kim B, Choe Y . Introduction of Methyl Groups at C2 and C6 Positions Enhances the Antiangiogenesis Activity of Curcumin. Sci Rep. 2015; 5:14205. PMC: 4585748. DOI: 10.1038/srep14205. View

Cen L, Carlson B, Pokorny J, Mladek A, Grogan P, Schroeder M . Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol. 2013; 15(6):735-46. PMC: 3661094. DOI: 10.1093/neuonc/not010. View

10.

Roos W, Batista L, Naumann S, Wick W, Weller M, Menck C . Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2006; 26(2):186-97. DOI: 10.1038/sj.onc.1209785. View

11.

Zinzi L, Capparelli E, Cantore M, Contino M, Leopoldo M, Colabufo N . Small and Innovative Molecules as New Strategy to Revert MDR. Front Oncol. 2014; 4:2. PMC: 3896858. DOI: 10.3389/fonc.2014.00002. View

12.

Reardon D, Rich J, Friedman H, Bigner D . Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006; 24(8):1253-65. DOI: 10.1200/JCO.2005.04.5302. View

13.

Dent E, Baas P . Microtubules in neurons as information carriers. J Neurochem. 2013; 129(2):235-9. PMC: 3979999. DOI: 10.1111/jnc.12621. View

14.

Kleihues P, Sobin L . World Health Organization classification of tumors. Cancer. 2000; 88(12):2887. DOI: 10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f. View

15.

Colabufo N, Berardi F, Perrone M, Cantore M, Contino M, Inglese C . Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009; 4(2):188-95. DOI: 10.1002/cmdc.200800329. View

16.

Choi M, No E, Thorat D, Jang J, Yang H, Lee J . Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy. J Med Chem. 2013; 56(22):9008-18. DOI: 10.1021/jm400840p. View

17.

Xia W, Fu W, Cai X, Wang M, Chen H, Xing W . Angiogenin promotes U87MG cell proliferation by activating NF-κB signaling pathway and downregulating its binding partner FHL3. PLoS One. 2015; 10(2):e0116983. PMC: 4320115. DOI: 10.1371/journal.pone.0116983. View

18.

Woo S, Ham Y, Kang W, Yang H, Kim S, Jin J . KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int. 2014; 2014:747415. PMC: 4176651. DOI: 10.1155/2014/747415. View

19.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

20.

Jordan M . Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2003; 2(1):1-17. DOI: 10.2174/1568011023354290. View